注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
IDEAYA Biosciences Inc是一家以合成致死性为重点的精准医学肿瘤公司。该公司从事发现和开发针对使用分子诊断法选择的病人群体的靶向治疗方法。其主要候选产品是darovasertib(IDE196)、IDE397和IDE161。IDE196是一种小分子蛋白激酶C(PKC)抑制剂,与克唑替尼(一种正在研究的cMET抑制剂)联合使用。IDE397是其小分子蛋氨酸腺苷转移酶2a(MAT2A)的抑制剂。IDE161是其小分子聚(ADP-核糖)糖化酶(PARG)的抑制剂。IDE196是其临床阶段的PKC抑制剂,该公司正在评估其作为一种合成致死性组合疗法。IDE397,是一种MAT2A抑制剂,用于有MTAP缺失的实体瘤患者。IDE161是其临床阶段的PARG的强效和选择性小分子抑制剂,用于具有基于基因突变和、或分子特征的确定生物标志物的肿瘤患者。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Alan D. D'Andrea | - | - | Chairman of Scientific Advisory Board |
Terry J. Rosen | 63 | 2016 | Independent Chairman of the Board |
Trey Ideker | - | 2016 | Member of Scientific Advisory Board |
Wendy L. Yarno | 68 | 2019 | Independent Director |
William R. Sellers | 62 | 2019 | Member of Scientific Advisory Board |
Elizabeth Swisher | - | 2016 | Member of Scientific Advisory Board |
Malcolm Garret Hampton | 57 | 2020 | Independent Director |
Jeffrey L. Stein | 68 | 2015 | Independent Director |
Scott W. Morrison | 65 | 2018 | Independent Director |
Frank P. McCormick | 73 | 2019 | Chair of Scientific Advisory Board |
Susan L. Kelley | 68 | 2021 | Independent Director |
Catherine J. Mackey | 68 | 2022 | Independent Director |
Karlene Cimprich | - | 2022 | Member of Scientific Advisory Board |
Kornelia Polyak | - | 2022 | Member of Scientific Advisory Board |
Yujiro S. Hata | 50 | 2015 | President, CEO & Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核